Browse FOXL2

Summary
SymbolFOXL2
Nameforkhead box L2
Aliases BPES1; BPES; PFRK; PINTO; POF3; forkhead transcription factor FOXL2; Forkhead box protein L2
Chromosomal Location3q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus
Domain PF00250 Forkhead domain
Function

Transcriptional regulator. Critical factor essential for ovary differentiation and maintenance, and repression of the genetic program for somatic testis determination. Prevents trans-differentiation of ovary to testis through transcriptional repression of the Sertoli cell-promoting gene SOX9 (By similarity). Has apoptotic activity in ovarian cells. Suppresses ESR1-mediated transcription of PTGS2/COX2 stimulated by tamoxifen (By similarity). Is a regulator of CYP19 expression (By similarity). Participates in SMAD3-dependent transcription of FST via the intronic SMAD-binding element (By similarity). Is a transcriptional repressor of STAR. Activates SIRT1 transcription under cellular stress conditions. Activates transcription of OSR2.

> Gene Ontology
 
Biological Process GO:0000737 DNA catabolic process, endonucleolytic
GO:0001541 ovarian follicle development
GO:0001555 oocyte growth
GO:0001654 eye development
GO:0002074 extraocular skeletal muscle development
GO:0006308 DNA catabolic process
GO:0006309 apoptotic DNA fragmentation
GO:0006921 cellular component disassembly involved in execution phase of apoptosis
GO:0007281 germ cell development
GO:0007292 female gamete generation
GO:0007338 single fertilization
GO:0007423 sensory organ development
GO:0007517 muscle organ development
GO:0007519 skeletal muscle tissue development
GO:0007530 sex determination
GO:0007548 sex differentiation
GO:0008406 gonad development
GO:0008585 female gonad development
GO:0009566 fertilization
GO:0009914 hormone transport
GO:0009994 oocyte differentiation
GO:0010817 regulation of hormone levels
GO:0010950 positive regulation of endopeptidase activity
GO:0010952 positive regulation of peptidase activity
GO:0014706 striated muscle tissue development
GO:0016049 cell growth
GO:0018993 somatic sex determination
GO:0019101 female somatic sex determination
GO:0019439 aromatic compound catabolic process
GO:0022412 cellular process involved in reproduction in multicellular organism
GO:0022601 menstrual cycle phase
GO:0022602 ovulation cycle process
GO:0023061 signal release
GO:0030237 female sex determination
GO:0030262 apoptotic nuclear changes
GO:0032274 gonadotropin secretion
GO:0032275 luteinizing hormone secretion
GO:0032276 regulation of gonadotropin secretion
GO:0032278 positive regulation of gonadotropin secretion
GO:0033684 regulation of luteinizing hormone secretion
GO:0033686 positive regulation of luteinizing hormone secretion
GO:0034655 nucleobase-containing compound catabolic process
GO:0042698 ovulation cycle
GO:0042703 menstruation
GO:0043010 camera-type eye development
GO:0043280 positive regulation of cysteine-type endopeptidase activity involved in apoptotic process
GO:0043281 regulation of cysteine-type endopeptidase activity involved in apoptotic process
GO:0044057 regulation of system process
GO:0044060 regulation of endocrine process
GO:0044270 cellular nitrogen compound catabolic process
GO:0044848 biological phase
GO:0045137 development of primary sexual characteristics
GO:0045862 positive regulation of proteolysis
GO:0046545 development of primary female sexual characteristics
GO:0046660 female sex differentiation
GO:0046700 heterocycle catabolic process
GO:0046879 hormone secretion
GO:0046880 regulation of follicle-stimulating hormone secretion
GO:0046881 positive regulation of follicle-stimulating hormone secretion
GO:0046883 regulation of hormone secretion
GO:0046884 follicle-stimulating hormone secretion
GO:0046887 positive regulation of hormone secretion
GO:0048048 embryonic eye morphogenesis
GO:0048477 oogenesis
GO:0048511 rhythmic process
GO:0048562 embryonic organ morphogenesis
GO:0048568 embryonic organ development
GO:0048588 developmental cell growth
GO:0048592 eye morphogenesis
GO:0048599 oocyte development
GO:0048608 reproductive structure development
GO:0050886 endocrine process
GO:0051047 positive regulation of secretion
GO:0052547 regulation of peptidase activity
GO:0052548 regulation of endopeptidase activity
GO:0060014 granulosa cell differentiation
GO:0060065 uterus development
GO:0060537 muscle tissue development
GO:0060538 skeletal muscle organ development
GO:0060986 endocrine hormone secretion
GO:0061458 reproductive system development
GO:0090305 nucleic acid phosphodiester bond hydrolysis
GO:0090596 sensory organ morphogenesis
GO:0097194 execution phase of apoptosis
GO:1901361 organic cyclic compound catabolic process
GO:1903532 positive regulation of secretion by cell
GO:2000116 regulation of cysteine-type endopeptidase activity
GO:2001056 positive regulation of cysteine-type endopeptidase activity
Molecular Function GO:0000978 RNA polymerase II core promoter proximal region sequence-specific DNA binding
GO:0000982 transcription factor activity, RNA polymerase II core promoter proximal region sequence-specific binding
GO:0000987 core promoter proximal region sequence-specific DNA binding
GO:0001077 transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding
GO:0001159 core promoter proximal region DNA binding
GO:0001228 transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding
GO:0030331 estrogen receptor binding
GO:0031624 ubiquitin conjugating enzyme binding
GO:0035257 nuclear hormone receptor binding
GO:0035258 steroid hormone receptor binding
GO:0043028 cysteine-type endopeptidase regulator activity involved in apoptotic process
GO:0044390 ubiquitin-like protein conjugating enzyme binding
GO:0051427 hormone receptor binding
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolFOXL2
Nameforkhead box L2
Aliases BPES1; BPES; PFRK; PINTO; POF3; forkhead transcription factor FOXL2; Forkhead box protein L2
Chromosomal Location3q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between FOXL2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolFOXL2
Nameforkhead box L2
Aliases BPES1; BPES; PFRK; PINTO; POF3; forkhead transcription factor FOXL2; Forkhead box protein L2
Chromosomal Location3q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of FOXL2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolFOXL2
Nameforkhead box L2
Aliases BPES1; BPES; PFRK; PINTO; POF3; forkhead transcription factor FOXL2; Forkhead box protein L2
Chromosomal Location3q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of FOXL2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.6350.0402
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-1.1210.0566
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.290.517
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.560.536
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-1.0560.478
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.0740.964
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.180.823
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-1.0810.487
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.7870.636
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 4801
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 2801
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0380.909
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of FOXL2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolFOXL2
Nameforkhead box L2
Aliases BPES1; BPES; PFRK; PINTO; POF3; forkhead transcription factor FOXL2; Forkhead box protein L2
Chromosomal Location3q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of FOXL2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolFOXL2
Nameforkhead box L2
Aliases BPES1; BPES; PFRK; PINTO; POF3; forkhead transcription factor FOXL2; Forkhead box protein L2
Chromosomal Location3q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of FOXL2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by FOXL2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolFOXL2
Nameforkhead box L2
Aliases BPES1; BPES; PFRK; PINTO; POF3; forkhead transcription factor FOXL2; Forkhead box protein L2
Chromosomal Location3q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of FOXL2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolFOXL2
Nameforkhead box L2
Aliases BPES1; BPES; PFRK; PINTO; POF3; forkhead transcription factor FOXL2; Forkhead box protein L2
Chromosomal Location3q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of FOXL2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolFOXL2
Nameforkhead box L2
Aliases BPES1; BPES; PFRK; PINTO; POF3; forkhead transcription factor FOXL2; Forkhead box protein L2
Chromosomal Location3q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between FOXL2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolFOXL2
Nameforkhead box L2
Aliases BPES1; BPES; PFRK; PINTO; POF3; forkhead transcription factor FOXL2; Forkhead box protein L2
Chromosomal Location3q23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting FOXL2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.